A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

NCT ID: NCT04965675

Last Updated: 2025-11-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

285 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-30

Study Completion Date

2026-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study includes a single intravenous (IV) infusion of the study drug and consists of a screening period (4 weeks), a double-blind, placebo-controlled period (12 weeks), and a safety follow-up period (8 weeks). Participants confirmed eligible will be randomized (1:1:1) to receive a single IV infusion of either eptinezumab 300 milligrams (mg) dose (weight adjusted; targeting adult exposure after 300 mg IV), eptinezumab 100 mg (weight adjusted; targeting adult exposure after 100 mg IV), or placebo at randomization visit. The doses will be adjusted for the participant's body weight.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Migraine in Children

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Eptinezumab 300 mg

Participants will receive a single IV infusion of eptinezumab 300 mg (weight adjusted).

Group Type EXPERIMENTAL

Eptinezumab

Intervention Type DRUG

Eptinezumab will be administered per dose and schedule specified in the arm.

Eptinezumab 100 mg

Participants will receive a single IV infusion of eptinezumab 100 mg (weight adjusted).

Group Type EXPERIMENTAL

Eptinezumab

Intervention Type DRUG

Eptinezumab will be administered per dose and schedule specified in the arm.

Placebo

Participants will receive a single IV infusion of placebo matching to eptinezumab.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo matching to eptinezumab will be administered per schedule specified in the arm.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Eptinezumab

Eptinezumab will be administered per dose and schedule specified in the arm.

Intervention Type DRUG

Placebo

Placebo matching to eptinezumab will be administered per schedule specified in the arm.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vyepti

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The participant has a diagnosis of migraine (with or without aura) as defined by International Classification of Headache Disorders 3 (ICHD-3) guidelines with history of chronic migraine, of at least 6 months prior to the screening visit.
* During the 28-day screening period, the participant must adequately complete the headache eDiary on at least 23 of the 28 days following the screening visit.
* During the 28-day screening period, the participant must have ≥15 to ≤26 headache days, of which at least 8 are migraine days as documented in the eDiary.

Exclusion Criteria

* The participant has previously been randomised in this study and exposed to eptinezumab.
* The participant has been exposed to any monoclonal antibody treatment (including exposure in a study) \<6 months prior to the screening visit.
* The participant has been exposed to another calcitonin gene-related peptide (CGRP) antibody (including exposure in a study investigating a CGRP antibody) \<6 months prior to the screening visit.
* The participant has a history or diagnosis of complicated migraine (ICHD-3 version, 2018), chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), migraine with brainstem aura, ophthalmoplegic migraine, or migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration; for example \>60 minutes).
Minimum Eligible Age

12 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

H. Lundbeck A/S

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Email contact via H. Lundbeck A/S

Role: STUDY_DIRECTOR

H. Lundbeck A/S

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Yale-New Haven Children's Hospital - PIN

New Haven, Connecticut, United States

Site Status RECRUITING

Ki Health Partners LLC DBA New England Institute for Clinical Research

Stamford, Connecticut, United States

Site Status RECRUITING

Children's National Medical Center

Washington D.C., District of Columbia, United States

Site Status RECRUITING

NW FL Clinical Research Group, LLC

Gulf Breeze, Florida, United States

Site Status RECRUITING

A G A Clinical Trials

Hialeah, Florida, United States

Site Status RECRUITING

Axcess Medical Research

Loxahatchee Groves, Florida, United States

Site Status COMPLETED

University of South Florida

Tampa, Florida, United States

Site Status RECRUITING

University of Kentucky HealthCare (UKHC) Kentucky Clinic

Lexington, Kentucky, United States

Site Status RECRUITING

University of Maryland

Baltimore, Maryland, United States

Site Status RECRUITING

Michigan Head Pain and Neurological Institute

Ann Arbor, Michigan, United States

Site Status COMPLETED

Michigan State University - Department of Neurology

East Lansing, Michigan, United States

Site Status COMPLETED

Corewell Health Butterworth Hospital

Grand Rapids, Michigan, United States

Site Status RECRUITING

Dent Neurosciences Research Center Incorporated

Amherst, New York, United States

Site Status COMPLETED

North Suffolk Neurology-Commack

Commack, New York, United States

Site Status RECRUITING

OnSite Clinical Solutions, LLC - Randolph Rd - Charlotte

Charlotte, North Carolina, United States

Site Status COMPLETED

Cincinnati Children's Hospital Medical Center - PIN

Cincinnati, Ohio, United States

Site Status RECRUITING

The University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, United States

Site Status COMPLETED

Road Runner Research Ltd

San Antonio, Texas, United States

Site Status RECRUITING

Children's Specialty Group

Norfolk, Virginia, United States

Site Status RECRUITING

Mary Bridge Children's Hospital

Tacoma, Washington, United States

Site Status COMPLETED

Marshall University Medical Center

Huntington, West Virginia, United States

Site Status RECRUITING

Hospital Privado de La Comunidad

Mar del Plata, Buenos Aires, Argentina

Site Status COMPLETED

Clínica Privada Independencia

Munro, Buenos Aires, Argentina

Site Status COMPLETED

Expertia S.A- Mautalén Salud e Investigación

Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina

Site Status RECRUITING

Hospital Britanico de Buenos Aires

Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina

Site Status ACTIVE_NOT_RECRUITING

Hospital Italiano de Buenos Aires

Ciudad Autónoma Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina

Site Status COMPLETED

Sanatorio Allende S.A

Córdoba, Córdoba Province, Argentina

Site Status COMPLETED

Hospital de Niños de La Santisima Trinidad

Córdoba-Barrio Crisol, Córdoba Province, Argentina

Site Status RECRUITING

Instituto Médico Río Cuarto

Río Cuarto, Córdoba Province, Argentina

Site Status RECRUITING

INECO Neurociencias Oroño

Rosario, Santa Fe Province, Argentina

Site Status RECRUITING

Centro de Investigaciones Médicas Tucumán - PPDS

San Miguel de Tucumán, Tucumán Province, Argentina

Site Status RECRUITING

University of Alberta

Edmonton, Alberta, Canada

Site Status COMPLETED

Medical Arts Health Research Group - Penticton

Penticton, British Columbia, Canada

Site Status COMPLETED

Vancouver Island Health Authority

Victoria, British Columbia, Canada

Site Status RECRUITING

The Kids Clinic

Ajax, Ontario, Canada

Site Status RECRUITING

London Health Sciences Centre -800 Commissioners Rd E

London, Ontario, Canada

Site Status RECRUITING

Azienda Ospedaliero Universitaria Consorziale Policlinico

Bari, Apulia, Italy

Site Status COMPLETED

Ospedale Pediatrico Bambino Gesù IRCCS

Rome, Lazio, Italy

Site Status RECRUITING

IRCCS Istituto Giannina Gaslini

Genoa, Liguria, Italy

Site Status RECRUITING

Ospedale San Raffaele S.r.l. - INCIPIT - PIN

Milan, Lombardy, Italy

Site Status RECRUITING

Fondazione IRCCS Istituto Neurologico Carlo Besta

Milan, Lombardy, Italy

Site Status COMPLETED

Fondazione Istituto Neurologico Nazionale Casimiro Mondino IRCCS

Pavia, Lombardy, Italy

Site Status RECRUITING

AO Brotzu - Clinica di Neuropsichiatria dell'Infanzia e dell'Adolescenza - INCIPIT - PIN

Cagliari, Sardinia, Italy

Site Status RECRUITING

Azienda Ospedaliero Universitaria A Meyer - INCIPIT - PIN

Florence, Tuscany, Italy

Site Status RECRUITING

Centro de Investigacion Medico Biologica y de Terapia Avanzada S.C.

Guadalajara, Jalisco, Mexico

Site Status RECRUITING

Unidad de Investigación en Salud de Chihuahua S.C.

Zapopan, Jalisco, Mexico

Site Status RECRUITING

Centro de Investigacion Clinica Chapultepec S.A. de C.V. - Morelia

Morelia, Michoacán, Mexico

Site Status RECRUITING

ICARO Investigaciones en Medicina, S.A de C.V

Chihuahua City, , Mexico

Site Status RECRUITING

Neurociencias Estudios Clinicos S.C.

Culiacán Sinaloa, , Mexico

Site Status COMPLETED

Instituto de Investigationes Clinicas para la Salud A.C.

Durango, , Mexico

Site Status RECRUITING

Unidad de Investigación en Salud de Chihuahua S.C.-Mexico city

Mexico City, , Mexico

Site Status COMPLETED

Clinical Research Institute SC-Mexico

Tepetlacolco, , Mexico

Site Status RECRUITING

Centro de Estudios Clinicos Y Especialidades Medicas SC

Vista Hermosa, , Mexico

Site Status COMPLETED

AthleticoMed

Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

Site Status RECRUITING

ETG Neuroscience - PPDS

Warsaw, Masovian Voivodeship, Poland

Site Status RECRUITING

Centrum Medyczne Plejady Magdalena Celinska - Lowenhoff, Michal Zolnowski Spolka komandytowa

Krakow, , Poland

Site Status RECRUITING

ETG Lublin - PPDS

Lublin, , Poland

Site Status RECRUITING

Instytut Zdrowia Dr Boczarska-Jedynak Sp. z o.o. Sp. k.

Oświęcim, , Poland

Site Status RECRUITING

MTZ Clinical Research Powered by PRATIA - PPDS

Warsaw, , Poland

Site Status RECRUITING

MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak

Wroclaw, , Poland

Site Status RECRUITING

ULS de Almada-Seixal, EPE - Hospital Garcia de Orta

Almada, Setúbal District, Portugal

Site Status RECRUITING

ULS de Coimbra, EPE - Hospital Pediátrico de Coimbra

Coimbra, , Portugal

Site Status RECRUITING

ULS de São João, EPE - Hospital de São João

Porto, , Portugal

Site Status RECRUITING

Childrens University Hospital

Belgrade, , Serbia

Site Status RECRUITING

University Clinical Center Kragujevac

Kragujevac, , Serbia

Site Status RECRUITING

Children and Youth Health Care Institute of Vojvodina

Novi Sad, , Serbia

Site Status RECRUITING

Clinical Centre of Vojvodina

Novi Sad, , Serbia

Site Status RECRUITING

CHUVI - H.U. Alvaro Cunqueiro

Vigo, Pontevedra, Spain

Site Status RECRUITING

Hospital Universitario Vall d'Hebron - PPDS

Barcelona, , Spain

Site Status RECRUITING

Instituto del Sueño

Madrid, , Spain

Site Status COMPLETED

Hospital Clinico San Carlos

Madrid, , Spain

Site Status RECRUITING

Hospital Universitario Virgen del Rocio - PPDS

Seville, , Spain

Site Status RECRUITING

Hospital Universitari i Politecnic La Fe de Valencia

Valencia, , Spain

Site Status RECRUITING

Izmir City Hospital

Bayraklı, İzmir, Turkey (Türkiye)

Site Status RECRUITING

Eskisehir Osmangazi Universitesi Tip Fakultesi Hastanesi

Eskişehir, , Turkey (Türkiye)

Site Status RECRUITING

Istanbul Üniversitesi, Istanbul Tip Fakültesi, Nör

Fatih/Istanbul, , Turkey (Türkiye)

Site Status RECRUITING

Istanbul University Cerrahpasa Medical Faculty Hospital

Fatih/Istanbul, , Turkey (Türkiye)

Site Status COMPLETED

Mersin University Medical Faculty

Mersin, , Turkey (Türkiye)

Site Status RECRUITING

Royal Devon and Exeter Hospital NHS Trust - PPDS

Exeter, Devon, United Kingdom

Site Status COMPLETED

Queen Elizabeth University Hospital - PPDS

Glasgow, Lanarkshire, United Kingdom

Site Status RECRUITING

Great Ormond Street Hospital - PPDS

London, London, City of, United Kingdom

Site Status RECRUITING

Royal Hospital for Children and Young People - PIN

Edinburgh, Midlothian, United Kingdom

Site Status RECRUITING

James Paget University Hospitals NHS Foundation Trust

Great Yarmouth, Norfolk, United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Canada Italy Mexico Poland Portugal Serbia Spain Turkey (Türkiye) United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Email contact via H. Lundbeck A/S

Role: CONTACT

Phone: +45 36301311

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-001009-22

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

2024-510656-13-00

Identifier Type: CTIS

Identifier Source: secondary_id

19356A

Identifier Type: -

Identifier Source: org_study_id